CALC - CalciMedica, Inc.

1.7199
-0.090   -5.239%

Share volume: 39,832
Last Updated: 04-08-2025
Pharmaceutical Products/Pharmaceutical Preparations: 0.05%

PREVIOUS CLOSE
CHG
CHG%
$1.81
-0.09
-0.05%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Overview Charts Financials Fundamental analysis Historical prices Events Documents Notes Dividends
Fundamental analysis
30%
Profitability 0%
Dept financing 40%
Liquidity 58%
Performance 50%
Company vs Stock growth
vs
+ Add row to compare
Performance
5 Days
-5.50%
1 Month
-20.74%
3 Months
-43.05%
6 Months
-56.97%
1 Year
-60.28%
2 Year
-37.46%
Key data
Stock price
$1.72
P/E Ratio 
0.00
DAY RANGE
$1.61 - $1.88
EPS 
-$1.22
52 WEEK RANGE
$1.57 - $6.26
52 WEEK CHANGE
-$61.00
MARKET CAP 
47.726 M
YIELD 
N/A
SHARES OUTSTANDING 
10.750 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
05-12-2025
BETA 
-0.26
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$31,239
AVERAGE 30 VOLUME 
$58,456
Company detail
CEO: Frédéric Guerard
Region: US
Website: calcimedica.com
Employees: 30
IPO year: 2020
Issue type: Common Stock
Market: XNAS
Industry: Pharmaceutical Products/Pharmaceutical Preparations
Sector: Manufacturing

CalciMedica, Inc. focuses on the development of medicines for the treatment of diseases of the retina and optic nerve. The company's lead product candidate is GB-102, an intravitreal injection of a microparticle depot formulation of sunitinib that is in Phase I/IIa and IIb clinical trials. GB-401, an implant formulation of a beta-adrenergic receptor inhibitor to treat primary open-angle glaucoma.

Recent news
loading